Medical Xpress December 31, 2024
Researchers are making strides in improving gene therapies for genetic diseases, particularly chronic kidney disease, using adeno-associated virus, or AAV, vectors. While AAV-based treatments have shown promise, delivering these therapies effectively to the kidneys has remained a challenge—until now.
There are many different types of AAV capsids—the protein shells of virus particles—that have been used to deliver genes to cells, each with unique effects. Most commonly, AAV capsids are delivered into the body via intravenous injection, but this method has limited success in targeting kidney cells and can sometimes cause harmful side effects, especially to the liver.
New research by Oregon Health & Science University scientists, however, has uncovered multiple factors to improve gene delivery to the kidney, including AAV...
Today's Sponsors
Today's Sponsor